Voyager Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Voyager Therapeutics (NASDAQ:VYGR) reported Q4 earnings with an EPS of $1.25, surpassing the estimated -$0.29 by 531.0%. Revenue increased by $91.61 million from the same period last year. Despite missing EPS estimates last quarter by $0.01, the share price increased by 5.0% the following day. The company has shown varied performance over the past quarters, with significant fluctuations in EPS and revenue.

February 28, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Voyager Therapeutics reported a significant beat on Q4 earnings estimates with an EPS of $1.25 against an expected -$0.29 and a substantial year-over-year revenue increase.
The substantial beat on both earnings and revenue expectations for Q4 indicates strong financial health and operational efficiency, likely leading to positive investor sentiment and a potential increase in stock price in the short term. Historical data shows a positive share price movement following earnings announcements, especially with significant beats.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100